Claudy A L, de Bouteiller O, Touraine J L
Dermatologica. 1984;169(1):18-22. doi: 10.1159/000249561.
Trimethylmethoxyphenyl-retinoic acid (TMMPRA), the main active therapeutic form of etretinate, was used for in vitro studies on human lymphocytes. Lymphocyte DNA synthesis remained unchanged when TMMPRA was added to the cultures at a concentration range of 1.25-25 micrograms/ml culture medium. No modulatory activity of the drug on DNA synthesis was seen on cultured lymphocytes stimulated by lectins (phytohemagglutinin, pokeweed mitogen, concanavalin A) or by a mitogen selective for a T lymphocyte subpopulation, phorbol myristate acetate. Concanavalin A induced T suppressor cell activity tested toward the proliferative response to allogeneic stimuli was lowered by TMMPRA. The results indicated that TMMPRA alone or in the presence of lectins or phorbol myristate acetate did not inhibit or stimulate DNA synthesis activity in vitro but that the drug could lower T suppressor cell activity.
三甲氧基苯基维甲酸（TMMPRA）是阿维A酯的主要活性治疗形式，用于对人淋巴细胞进行体外研究。当在培养基中以1.25 - 25微克/毫升的浓度范围添加TMMPRA时，淋巴细胞DNA合成保持不变。在由凝集素（植物血凝素、商陆有丝分裂原、刀豆球蛋白A）或对T淋巴细胞亚群具有选择性的有丝分裂原佛波酯刺激的培养淋巴细胞上，未观察到该药物对DNA合成的调节活性。刀豆球蛋白A诱导的针对同种异体刺激的增殖反应的T抑制细胞活性被TMMPRA降低。结果表明，单独的TMMPRA或在存在凝集素或佛波酯的情况下，在体外均不抑制或刺激DNA合成活性，但该药物可降低T抑制细胞活性。
